# A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

> **NCT04708184** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3970 oral solution
- **DRUG:** GLPG3970 tablet

## Key facts

- **NCT ID:** NCT04708184
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-11
- **Primary completion:** 2021-02-25
- **Final completion:** 2021-02-25
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04708184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04708184, "A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04708184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*